Skip to content
Business websites
Business websites
J&J Innovative Medicine
J&J MedTech
J&J Innovative Medicine
J&J MedTech
Location
Language
English
Choose your country or region
China
中国人
France
Français
India
English
Japan
日本
Switzerland
Deutsch
English
Français
US
English
UK
English
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Our culture of inclusion
ESG Policies & Positions
Innovation at J&J
Uniting science and technology
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Our heritage
Careers
Search jobs
Life at J&J
Employee benefits
Professional development
Employee stories
Our teams
Oncology
Immunology
Data science
Market access
Medical affairs
Innovation, development and partnerships
MedTech and surgical robotics
Locations
North America
EMEA
Asia Pacific
Latin America
Student opportunities
Internships
Co-ops
Full-time student jobs
Leadership and development opportunities
How we hire
Application tips
Hiring programs
Hiring FAQs
Join our Global Talent Hub
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Press releases
Menu
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Our culture of inclusion
ESG Policies & Positions
Innovation at J&J
Uniting science and technology
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Our heritage
Careers
Search jobs
Life at J&J
Employee benefits
Professional development
Employee stories
Our teams
Oncology
Immunology
Data science
Market access
Medical affairs
Innovation, development and partnerships
MedTech and surgical robotics
Locations
North America
EMEA
Asia Pacific
Latin America
Student opportunities
Internships
Co-ops
Full-time student jobs
Leadership and development opportunities
How we hire
Application tips
Hiring programs
Hiring FAQs
Join our Global Talent Hub
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Press releases
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Show Search
Home
/
Media Center
/
Press releases
Press releases
Press Releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
2,123 Results
Date
All Dates (2123)
Past 30 days (21)
2023 (139)
2022 (124)
2021 (184)
2020 (109)
2019 (130)
2018 (166)
2017 (194)
2016 (125)
Topic
All (2123)
Corporate (147)
Financial (303)
Innovative Medicine (962)
Leadership (20)
Medical technologies (293)
Research (41)
2,123 results
Filters
Date
All Dates (2123)
Past 30 days (21)
2023 (139)
2022 (124)
2021 (184)
2020 (109)
2019 (130)
2018 (166)
2017 (194)
2016 (125)
Topic
All (2123)
Corporate (147)
Financial (303)
Innovative Medicine (962)
Leadership (20)
Medical technologies (293)
Research (41)
Sort By:
Newest
Newest
Relevance
Oldest
April 28, 2025
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
Read more
April 26, 2025
Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population
Read more
April 26, 2025
Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive, high-risk non-muscle invasive bladder cancer
Read more
April 25, 2025
Johnson & Johnson MedTech Presents 3-Month Data from Omny-IRE Clinical Trial at 2025 Heart Rhythm Society Annual Meeting
Omny-IRE data demonstrated the investigational OMNYPULSE™ Platform achieved 100% acute success and 84.5% pulmonary vein isolation (PVI) durability at three months, with promising safety outcomes1 Additional data presented from VARIPURE registry2 and Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter3 pre-clinical study underscore safety and real-world efficiency across Johnson & Johnson MedTech’s expanding pulsed field ablation portfolio
Read more
Innovative Medicine
April 21, 2025
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2) Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer
Read more
April 16, 2025
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
Read more
April 15, 2025
Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%
Read more
Financial
April 15, 2025
Johnson & Johnson reports Q1 2025 results
• 2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* • 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* • Significant new product pipeline progress including approval of TREMFYA in Crohn’s disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA • Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the completion of the Intra-Cellular Therapies acquisition • Including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange, Company maintains Full-Year 2025 adjusted reported EPS4 outlook of 6.2%* growth at the mid-point
Read more
Medical technologies
April 14, 2025
Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA™ Robotic Surgical System
First use in gastric bypass at Memorial Hermann-Texas Medical Center Trial will support submission for multiple procedures
Read more
April 10, 2025
Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16
Read more
Load More